CLINICAL TRIAL COMPARING ARNI WITH ACE INHIBITORS IN POST SURGICAL PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION BY CLINICAL AND ECHOCARDIOGRAPHIC STUDY

CLINICAL AND ECHOCARDIOGRAPHIC EVALUATION OF POST SURGICAL PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION ON ARNI AND ACE INHIBITORS- A COMPARATIVE ANALYSIS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/09/015847

Enrollment

100

Registered

2018-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I502- Systolic (congestive) heart failure

Interventions

Intervention1: ARNI (ANGIOTENSIN RECEPTOR AND NEPRILYSIN INHIBITOR) A SACUBITRILVALSARTAN IN VARIABLE DOSAGE DEPENDING ON THE PATIENTS PROFILESTARTING FROM DOSE OF 50MG: ARNI (ANGIOTENSIN RECEPTOR AN

Eligibility

Inclusion criteria

Inclusion criteria: ALL POST CARDIAC SURGERY PATIENTS OF AGE ABOVE 18 YEARS WITH LEFT VENTRICULAR EJECTION FRACTION LESS THAN OR EQUAL TO 40 PERCENT ON CLINICAL AND ECHOCARDIOGRAPHIC EVALUATION WHO ARE READY TO GIVE INFORMED CONSENT.

Exclusion criteria

Exclusion criteria: 1 PATIENTS WITH MULTISYSTEM DISEASE 2 PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 3 PATIENTS WITH CHRONIC KIDNEY DISEASE WITH DECREASED CREATININE CLEARANCE LESS THAN 30ML 4 PATIENTS WITH SERUM POTASSIUM GREATER THAN 5.5 MMOL PER LITRE 5 PATIENTS WITH BILATERAL RENAL ARTERY STENOSIS 6 PATIENTS WITH SYSTOLIC BLOOD PRESSURE LESS THAN 90MMHG 7 PATIENTS WITH A KNOWN HOSTORY OF ANGIOEDEMA 8 PATIENTS WITH HISTORY OF HYPERSENSITIVITY TO SACUBITRILVALSARTAN OR DRUGS OF SIMILAR CHEMICAL CLASSES OR KNOWN INTOLERANCE OR CONTRAINDICATIONS TO STUDY DRUGS OR DRUGS OF SIMILAR CHEMICAL CLASSES INCLUDING ACE INHIBITORS ARB OR NEP INHIBITORS 9 PATIENTS UNWILLING TO ENROLL FOR THE STUDY

Design outcomes

Secondary

Measure	Time frame
ALL CAUSE MORTALITY CARDIOVASCULAR MORTALITY HOSPITALIZATION RATETimepoint: ALL CAUSE MORTALITY AT END OF 1 YEAR FOLLOW UP CARDIOVASCULAR MORTALITY AT END OF 1 YEAR FOLLOW UP HOSPITALIZATION RATE AT END OF 1 YEAR FOLLOW UP	—

Primary

Measure	Time frame
ALL CAUSE MORTALITY CARDIOVASCULAR MORTALITY HOSPITALIZATION RATETimepoint: ALL CAUSE MORTALITY AT END OF 1 YEAR FOLLOW UP CARDIOVASCULAR MORTALITY AT END OF 1 YEAR FOLLOW UP HOSPITALIZATION RATE AT END OF 1 YEAR FOLLOW UP	—

Countries

India

Contacts

Public ContactDR DHEERAJKUMAR GANDOTRA

DR. B L KAPUR MEMORIAL HOSPITAL, PUSA ROAD, NEW DELHI, 110005

dheerajk.gandotra@blkhospital.com9818994853

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026